MRK · News · 20260903N

Keytruda Patent Expiration Outlook

Merck & Co., Inc. · 2026-09-03 · Importance 50 · Surprise 24

Keytruda remains Merck’s principal growth driver, supporting recent sales momentum and investor interest. Third-party reporting warns that biosimilar competition could intensify around the drug’s expected 2028 patent cliff, creating a material threat to Merck’s oncology franchise. Merck’s pipeline and newer products are being positioned as potential offsets to the eventual erosion of Keytruda sales.

Key facts